US 12,187,752 B2
Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
Christopher J. Burns, Malvern, PA (US); Daniel C. Pevear, Downingtown, PA (US); Luigi Xerri, Wayne, PA (US); Timothy Henkel, Berwyn, PA (US); Daniel McGarry, Malvern, PA (US); Lawrence Rosen, Malvern, PA (US); Gerald Brenner, Plymouth, PA (US); Jean-Baptiste Arlin, Amsterdam (NL); and Ana Fernandez Casares, Amsterdam (NL)
Assigned to VENATORX PHARMACEUTICALS, INC., Malevern, PA (US)
Filed by Venatorx Pharmaceuticals, Inc., Malvern, PA (US)
Filed on Sep. 27, 2023, as Appl. No. 18/476,050.
Application 17/353,377 is a division of application No. 16/491,116, granted, now 11,091,505, issued on Aug. 17, 2021, previously published as PCT/US2018/020968, filed on Mar. 5, 2018.
Application 18/476,050 is a continuation of application No. 17/353,377, filed on Jun. 21, 2021, granted, now 11,820,784.
Claims priority of provisional application 62/564,989, filed on Sep. 28, 2017.
Claims priority of provisional application 62/564,990, filed on Sep. 28, 2017.
Claims priority of provisional application 62/467,752, filed on Mar. 6, 2017.
Claims priority of provisional application 62/467,750, filed on Mar. 6, 2017.
Prior Publication US 2024/0101580 A1, Mar. 28, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61P 31/04 (2006.01); A61K 9/00 (2006.01); A61K 31/546 (2006.01); A61K 31/69 (2006.01); A61K 47/02 (2006.01); A61K 47/12 (2006.01); A61K 47/18 (2017.01); A61K 47/26 (2006.01); C07F 5/02 (2006.01)
CPC C07F 5/027 (2013.01) [A61K 9/0095 (2013.01); A61K 47/02 (2013.01); A61K 47/12 (2013.01); A61K 47/183 (2013.01); A61K 47/26 (2013.01); A61P 31/04 (2018.01); A61K 9/0019 (2013.01); A61K 31/546 (2013.01)] 15 Claims
 
1. A pharmaceutical composition comprising:
(i) (R)-3-(2-(trans-4-(2-aminoethylamino)cyclohexyl) acetamido)-2-hydroxy-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylic acid:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt, a solvate, or a pharmaceutically acceptable salt and solvate thereof;
(ii) cefepime; and
(iii) L-arginine.